These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33805639)

  • 1. Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials.
    Dri DA; Marianecci C; Carafa M; Gaucci E; Gramaglia D
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33805639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office.
    Dri DA; Gaucci E; Torrieri I; Carafa M; Marianecci C; Gramaglia D
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office.
    Dri DA; Praticò G; Gaucci E; Marianecci C; Gramaglia D
    Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
    Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
    Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
    Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
    Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGylated nanomedicines: recent progress and remaining concerns.
    Vllasaliu D; Fowler R; Stolnik S
    Expert Opin Drug Deliv; 2014 Jan; 11(1):139-54. PubMed ID: 24295065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
    Ehmann F; Sakai-Kato K; Duncan R; Hernán Pérez de la Ossa D; Pita R; Vidal JM; Kohli A; Tothfalusi L; Sanh A; Tinton S; Robert JL; Silva Lima B; Amati MP
    Nanomedicine (Lond); 2013 May; 8(5):849-56. PubMed ID: 23656268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Requirements of Managing Phase I Clinical Trials Risks: The British and Italian Case Studies.
    Di Tonno D; Martena L; Taurisano M; Perlin C; Loiacono AC; Lagravinese S; Marsigliante S; Maffia M; Esposito S; Villa G; Gori G; Bray L; Distante A; Miani A; Piscitelli P; Argentiero A
    Epidemiologia (Basel); 2024 Mar; 5(1):137-145. PubMed ID: 38534806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines in the EU-Regulatory Overview.
    Pita R; Ehmann F; Papaluca M
    AAPS J; 2016 Nov; 18(6):1576-1582. PubMed ID: 27527889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination antitumor therapy with targeted dual-nanomedicines.
    Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
    Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
    Xoxi E; Facey KM; Cicchetti A
    Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Authorization of COVID-19 clinical trials: lessons from 2 years of experience of a national competent authority.
    Vignot S; Dhanani A; Sainte-Marie I; de Ligniville Lajavardi L; Even G; Echemann M; Hulin N; Ménoret C; Maison P; Ratignier-Carbonneil C
    Front Pharmacol; 2022; 13():972660. PubMed ID: 36046816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using GRADE methodology to assess innovation of new medicinal products in Italy.
    Fortinguerra F; Tafuri G; Trotta F; Addis A
    Br J Clin Pharmacol; 2020 Jan; 86(1):93-105. PubMed ID: 31656055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.